Imbruvica Approved For First line by Health Canada 🇨🇦
IMBRUVICA® significantly improved progression-free, overall survival, and overall response rate versus an established chemotherapy.
Janssen Inc. announced that Health Canada has approved IMBRUVICA® (ibrutinib) an oral, once-daily, single-agent targeted therapy for previously untreated patients with active chronic lymphocytic leukemia (CLL).1 This is the 4th approval for IMBRUVICA®, which now is approved for use in all lines of CLL therapy for patients needing treatment, considerably expanding the number of Canadian patients who may benefit from this chemotherapy-free treatment. Chronic lymphocytic leukemia is one of the most common types of leukemia in adults.
Idelalisib (Zydelig) gets pCODR final recommendation for Canada
Today, the pCODR Expert Review Committee (pERC) issued the final recommendation for idelalisib (Zydelig) for chronic lymphocytic leukemia (CLL).
pERC recommends funding idelalisib (Zydelig), conditional on cost-effectiveness being improved to an acceptable level, when used in combination with rituximab for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL). Treatment should continue until unacceptable toxicity or disease progression.
Wendy's Wish Inc was created to raise awareness of Richter's Transformation, to offer financial and peer support for those effected by Richter's Transformation, and to raise funding for research for Richter's Transformation. It was founded by Wendy Sonlin, a Richter's Transformation patient currently in remission.
People in Quebec living with Chronic Lymphocytic Leukemia (CLL) will now be able to access a new treatment option through the province's prescription drug insurance plan.
Just yesterday, GAZYVA® (obinutuzumab) in combination with chlorambucil chemotherapy was added to Quebec's Hospital Formulary. GAZYVA® was approved by Health Canada on November 25, 2014, in combination with chlorambucil, for the treatment of patients with previously untreated CLL.
Blood Cancer Research Fund Conference Speaker Videos
In honor of Miles Pendleton, a CLL patient and advocate, the CLL Research Consortium and the Blood Cancer Research Fund, hosted a patient education and empowerment meeting. The meeting took place at UC San Diego Moores Cancer Center, in La Jolla, California.
'While Health Canada has approved the use of Imbruvica, which patients could have to take for the rest of their lives, provinces have yet to decide whether they will foot the annual $100,000 per patient bill.'
Canadian cancer specialists meet next week to discuss whether to recommend Imbruvica for provincial coverage.
Roche Canada announced that Health Canada has approved GAZYVA™ (obinutuzumab) to be administered in combination with chlorambucil chemotherapy for the treatment of people with previously untreated CLL.
This is approval for safety and efficacy. It is not available or funded in the clinic yet.
Janssen Inc. announced today Health Canada has approved IMBRUVICA™ (ibrutinib) for the treatment of the blood cancer chronic lymphocytic leukemia (CLL). It is indicated for the treatment of patients with CLL, including those with 17p deletion, who have received at least one prior therapy, or for the frontline treatment of patients with CLL with 17p deletion.
In CLL, 17p deletion is a genetic mutation that has been associated with poor treatment outcomes.
This DOES NOT MEAN IT IS FUNDED by the provinces yet... it is the first step...
The National Institute for Health and Care Excellence (NICE) has issued draft guidance recommending GlaxoSmithKline's Arzerra (ofatumumab) in a form of leukaemia.
NICE, which provides health guidance for the NHS in England and Wales, said the drug was a cost-effective option in combination with chlorambucil for untreated chronic lymphocytic leukaemia (CLL) in people who are not eligible for treatment with fludarabine combination therapy and for whom bendamustine is unsuitable.
Ofatumumab’s list price is £182 for a 100 mg vial and £1820 for a 1000 mg vial. Assuming 6 cycles and no drug wastage, the mean cost of a treatment course for ofatumumab at its list price is £11,466 for 6300 mg. The company has agreed a patient access scheme with the Department of Health that makes ofatumumab available with a discount on the list price.
Nov 4, 2014
DailyMed provides trustworthy information about marketed drugs in the U.S.
DailyMed is the official provider of FDA label information (package inserts).
This new redesigned Web site provides a standard, comprehensive, up-to-date, look-up and download resource of medication content and labeling found in medication package inserts.
To view a specific section in the listing, click or tap on the 'orange plus, beside a topic. The information is also available in PDF format ...to download
This particular page link is for ibrutinib, but you can search any drug in the database of FDA approved treatments...
Oct 21, 2014
A Canadian Perspective on the Treatment of Unfit Patients with Chronic Lymphocytic Leukemia
This paper discusses two major issues physicians encounter when treating unfit patients with CLL: (i) What factors enter into the decision that a patient is unfit for FCR therapy? (ii) What are the best treatment options for those patients who are deemed unfit? In addition to reviewing the current evidence, the regional practices of three Canadian experts from Nova Scotia, Quebec, and Alberta will be explored.
PDF LINK HERE
Feb 3 , 2014
LLC en français?
This is a link to a French CLL/SLL website...
might give it a try.
Dec 10 , 2013
How Cancer Drugs are Approved and Funded in Canada
This tutorial explains the process that decision makers in Canada follow to decide whether to publicly fund new cancer drugs. You’ll learn who is involved in this process, and how health benefits, costs and values play into the decision. At the end of the tutorial, you should be able to answer the following questions:
Which groups make decisions in Canada about publicly funded cancer drugs and how are those decisions made?
◊ How do we know if drugs work and are better than current treatment?
◊ How do costs and benefits fit into the decision making process?
◊ What is a fair decision?
◊ How are decision makers held accountable to the public?
◊ How can you get involved in cancer drug funding decision making panels?
The principles described in this tutorial also apply to decisions about other non-
cancer drugs and new health care technologies.
LINK HERE PDF TUTORIAL
Nov 2, 2013
Flow Cytometry ~ Everything you need to know and more...
Flow Cytometry is a blood test used to diagnose CLL. This video tutorial education program explains how flow cytometry actually works.
This takes about 12 minutes to view... Will NOT work on iPad etc. Needs Flash Player 8
Information on the CLL CANADA website (www.cllcanada.ca) is intended to be used for general information and educational purposes
and should not replace consultation with healthcare professionals. The information on this site is provided by CLL patients and caregivers.
Consult a qualified healthcare professional before making any medical decisions or if you have questions about your individual medical situation. Please, do not self medicate.